LRMR - Larimar Therapeutics

-

$undefined

N/A

(N/A)

Larimar Therapeutics NasdaqGM:LRMR Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Location: Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States | Website: https://larimartx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-25.88M

Cash

157.5M

Avg Qtr Burn

-21.72M

Short % of Float

21.98%

Insider Ownership

1.43%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.